METTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy

Le résumé fourni par la source

The abundance and activity of estrogen receptor alpha (ERα) are tightly regulated by ubiquitin-specific peptidase 22 (USP22) during the progression of breast cancer (BCa). However, the post-transcriptional modifications on the USP22-ERα axis remain elusive. N6-methyladenosine (m 6 A) is critical to modulate RNA status in eukaryotic cells. Here, we find that METTL14 positively regulates the mRNA expression of USP22 and ERα. Mechanistically, METTL14 potently binds to the USP22 and ERα mRNA, and thereby enhancing their stability through m 6 A modification. YTHDC1 and YTHDF1 function as readers for m 6 A-modified USP22 and ERα, respectively. Additionally, METTL14 promotes the growth and migration of ERα + BCa via the USP22-ERα-Cyclin D1 axis. Enforced expression of USP22/ERα significantly reverses the METTL14 depletion-induced growth and migration inhibition in BCa. Moreover, our analysis of clinical samples shows that the expression of METTL14, USP22, and ERα is upregulated and correlated in BCa tissues. Overall, our findings reveal the key role of the METTL14-USP22-ERα axis in BCa progression, which further provides a druggable target to treat BCa. • METTL14 upregulates mRNA stability of USP22 and ERα through m 6 A modification. • The METTL14-USP22/ERα axis is critical to boost breast cancer development. • METTL14 is a potential target for better management of ERα positive breast cancer.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.